Cargando…

Mesenchymal Stromal Cells as a Driver of Inflammaging

Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyamina, Svetlana, Baranovskii, Denis, Kozhevnikova, Ekaterina, Ivanova, Tatiana, Kalish, Sergey, Sadekov, Timur, Klabukov, Ilya, Maev, Igor, Govorun, Vadim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094085/
https://www.ncbi.nlm.nih.gov/pubmed/37047346
http://dx.doi.org/10.3390/ijms24076372
_version_ 1785023753161277440
author Lyamina, Svetlana
Baranovskii, Denis
Kozhevnikova, Ekaterina
Ivanova, Tatiana
Kalish, Sergey
Sadekov, Timur
Klabukov, Ilya
Maev, Igor
Govorun, Vadim
author_facet Lyamina, Svetlana
Baranovskii, Denis
Kozhevnikova, Ekaterina
Ivanova, Tatiana
Kalish, Sergey
Sadekov, Timur
Klabukov, Ilya
Maev, Igor
Govorun, Vadim
author_sort Lyamina, Svetlana
collection PubMed
description Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidence showed that the majority of age-associated ailments, i.e., diabetes mellitus, cardiovascular diseases and neurodegeneration. These diseases are closely associated with tissue nonspecific inflammation triggered and controlled by mesenchymal stromal cell secretion. Mesenchymal stromal cells (MSCs) are known as the most common type of cells for therapeutic approaches in clinical practice. Side effects and complications of MSC-based treatments increased interest in the MSCs secretome as an alternative concept for validation tests in regenerative medicine. The most recent data also proposed it as an ideal tool for cell-free regenerative therapy and tissue engineering. However, senescent MSCs secretome was shown to hold the role of ‘key-driver’ in inflammaging. We aimed to review the immunomodulatory effects of the MSCs-secretome during cell senescence and provide eventual insight into the interpretation of its beneficial biological actions in inflammaging-associated diseases.
format Online
Article
Text
id pubmed-10094085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100940852023-04-13 Mesenchymal Stromal Cells as a Driver of Inflammaging Lyamina, Svetlana Baranovskii, Denis Kozhevnikova, Ekaterina Ivanova, Tatiana Kalish, Sergey Sadekov, Timur Klabukov, Ilya Maev, Igor Govorun, Vadim Int J Mol Sci Review Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidence showed that the majority of age-associated ailments, i.e., diabetes mellitus, cardiovascular diseases and neurodegeneration. These diseases are closely associated with tissue nonspecific inflammation triggered and controlled by mesenchymal stromal cell secretion. Mesenchymal stromal cells (MSCs) are known as the most common type of cells for therapeutic approaches in clinical practice. Side effects and complications of MSC-based treatments increased interest in the MSCs secretome as an alternative concept for validation tests in regenerative medicine. The most recent data also proposed it as an ideal tool for cell-free regenerative therapy and tissue engineering. However, senescent MSCs secretome was shown to hold the role of ‘key-driver’ in inflammaging. We aimed to review the immunomodulatory effects of the MSCs-secretome during cell senescence and provide eventual insight into the interpretation of its beneficial biological actions in inflammaging-associated diseases. MDPI 2023-03-28 /pmc/articles/PMC10094085/ /pubmed/37047346 http://dx.doi.org/10.3390/ijms24076372 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lyamina, Svetlana
Baranovskii, Denis
Kozhevnikova, Ekaterina
Ivanova, Tatiana
Kalish, Sergey
Sadekov, Timur
Klabukov, Ilya
Maev, Igor
Govorun, Vadim
Mesenchymal Stromal Cells as a Driver of Inflammaging
title Mesenchymal Stromal Cells as a Driver of Inflammaging
title_full Mesenchymal Stromal Cells as a Driver of Inflammaging
title_fullStr Mesenchymal Stromal Cells as a Driver of Inflammaging
title_full_unstemmed Mesenchymal Stromal Cells as a Driver of Inflammaging
title_short Mesenchymal Stromal Cells as a Driver of Inflammaging
title_sort mesenchymal stromal cells as a driver of inflammaging
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094085/
https://www.ncbi.nlm.nih.gov/pubmed/37047346
http://dx.doi.org/10.3390/ijms24076372
work_keys_str_mv AT lyaminasvetlana mesenchymalstromalcellsasadriverofinflammaging
AT baranovskiidenis mesenchymalstromalcellsasadriverofinflammaging
AT kozhevnikovaekaterina mesenchymalstromalcellsasadriverofinflammaging
AT ivanovatatiana mesenchymalstromalcellsasadriverofinflammaging
AT kalishsergey mesenchymalstromalcellsasadriverofinflammaging
AT sadekovtimur mesenchymalstromalcellsasadriverofinflammaging
AT klabukovilya mesenchymalstromalcellsasadriverofinflammaging
AT maevigor mesenchymalstromalcellsasadriverofinflammaging
AT govorunvadim mesenchymalstromalcellsasadriverofinflammaging